Friday, January 09, 2015 10:51:11 AM
RXII 1.55 (roi) Target 2.10
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering, developing, and commercializing therapies based on its proprietary, next-generation RNA interference (RNAi) platform. The company?s lead product candidate, RXI-109, is a self-delivering RNAi compound, which is in Phase II clinical trial for use in the reduction of dermal scarring. Its therapeutic development programs in the discovery and preclinical stages include products for the treatment of ocular scarring, liver fibrosis, joint fibrosis, and vascular restenosis. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering, developing, and commercializing therapies based on its proprietary, next-generation RNA interference (RNAi) platform. The company?s lead product candidate, RXI-109, is a self-delivering RNAi compound, which is in Phase II clinical trial for use in the reduction of dermal scarring. Its therapeutic development programs in the discovery and preclinical stages include products for the treatment of ocular scarring, liver fibrosis, joint fibrosis, and vascular restenosis. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
